ABSTRACT
Professor YANG Yun-kuan summarizes rich experiences on treatment of dermopathy with acupuncture and moxibustion in clinical and teaching practice of over 30 years. Here his unique therapy of cotton-sheet moxibustion is introduced. Different dermal diseases are treated with combination of cotton-sheet moxibustion with body acupuncture or skin needle, achieving good clinical effects. Cotton-sheet moxibustion has the characteristics of common materials and convenient manipulation. This is a safe, economic therapy with obvious therapeutic effect and it provides an effective way for treatment of dermopathy.
Subject(s)
Adult , Female , Humans , Male , Dermatitis , Therapeutics , History, 20th Century , History, 21st Century , Moxibustion , History , MethodsABSTRACT
<p><b>OBJECTIVE</b>To determine the expression of tumor suppressor gene PRDM1 in lung cancers.</p><p><b>METHODS</b>Forty-five cases were enrolled in this study, including squamous cell carcinoma (20 cases), adenocarcinoma (15 cases), and small cell cancer (10 cases). PRDM1 protein was detected in paraffin-embedded tissue by immunohistochemistry. Tumor cells in lung cancers were further selected by laser microdissection for RT-PCR analysis. PRDM1 protein in frozen tissue was also detected by Western blot.</p><p><b>RESULTS</b>(1) PRDM1 protein was found in paraffin-embedded tissues in 90.0% (18/20) of squamous cell carcinoma, 13.3% (2/15) of adenocarcinoma, and 0 (0/10) small cell lung cancer. Squamous cell carcinoma predominantly expressed PRDM1 protein ( P < 0.01). (2) Gene product of PRDM1 DNA binding region was not found in microdissected tumor cells, but an abnormal PRDM1 protein about 70 KD was detected simultaneously in whole tumor tissue.</p><p><b>CONCLUSION</b>PRDM1 may be considered as a specific biomarker in pulmonary squamous cell carcinoma. The abnormal PRDM1 expression both at transcriptional and protein levels indicated that this tumor suppressor gene lost its function, which may become a new target in the strategy of treatment for lung cancers.</p>
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Adenocarcinoma , Genetics , Metabolism , Biomarkers, Tumor , Genetics , Metabolism , Blotting, Western , Carcinoma, Small Cell , Genetics , Metabolism , Carcinoma, Squamous Cell , Genetics , Metabolism , Gene Expression Regulation, Neoplastic , Immunohistochemistry , Lung Neoplasms , Genetics , Metabolism , Positive Regulatory Domain I-Binding Factor 1 , Repressor Proteins , Genetics , Metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors , Genetics , MetabolismABSTRACT
The study was aimed to investigate the BCL-XL expression and mutation, and its clinical significance in non-Hodgkin's lymphoma. Lymphoma cells were selectively isolated by laser microdissection. BCL-XL expression from lymphoma tissue and microdissected lymphoma cells was measured by using real-time quantitative reverse transcription-polymerase chain reaction. BCL-XL mutation was analyzed by using direct sequencing of PCR products. The results showed that compared to 15 patients with reactive hyperplasia, BCL-XL was overexpressed in follicular lymphoma (n = 30), both in lymphoma tissue (P = 0.0064) and in microdissected lymphoma cells (P < 0.0001). No significant rise of BCL-XL expression was observed in patients with T-cell lymphoma (n = 24) and diffuse large B cell lymphoma (n = 24). In follicular lymphoma, high BCL-XL level was associated with multiple extranodal involvement (P = 0.0004), elevated lactate dehydrogenase level (P = 0.0019), high-risk international prognostic index (P = 0.0013) and a short overall survival time (P = 0.0451). Mutation analysis revealed one synonymous mutation (Codon 109 ACA-->ACC) in one case of follicular lymphoma patient. It is concluded that BCL-XL expression is closely correlated with progress of follicular lymphoma and prognosis of patients with follicular lymphoma. The value of BCL-XL expression as a prognostic marker in follicular lymphoma should be considered.